Pressure BioSciences Receives Record Nearly $600,000 Order for 16 PCT Instruments

Largest Single Order in Company's History was Prepaid as New Chinese Distributor Comes Online;

Adds to Revenue Strength Also Building Across PBI's UltraShear Nanoemulsions Platform

SOUTH EASTON, MA / ACCESSWIRE / February 1, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) ("PBI" or the "Company"), a global leader in the development and sale of broadly enabling, high-pressure-based products and services to the life sciences and other industries, today announced entrance into an exclusive distribution agreement for the People's Republic of China ("Agreement") with PRS International Trade (Shanghai) Co., Ltd. ("PRS International").

Reflecting confidence built upon PBIO's long investment in developing worldwide market support for the Company's Pressure Cycling Technology ("PCT") platform, PRS International prepaid for the entire purchase of 16 Barocycler EXT units for a total of nearly $600,000, with a commitment to purchase additional units and related consumables before the end of 2023. This historic purchase of PBIO's original high-pressure technology instruments comes on the back of a surge in purchase orders for all product categories of the Company's pressure-based instruments and consumables.

Director of Sales and Marketing John B. Hollister commented, "We believe this purchase of a record number of Barocycler EXT instruments, together with strong worldwide indications of purchase plans for additional non-PCT instruments and consumables, indicates that China and the rest of the life sciences world is finally emerging from under the economic cloud of COVID. We expect first quarter 2023 sales to benefit from the initial shipment of up to five Barocycler EXT instruments to China, from the surge in orders we are experiencing in our other pressure-based instrument areas (e.g., Barocyclers, HUB pressure generators, and cell disruptors), and from our recently opened UltraShear™ nanoemulsions tolling services. Adding to this excitement, we had a few expected sales in 2022 slip into 2023 due to supply chain issues. The net effect is that we are having a terrific first quarter, which we believe will continue to strengthen throughout 2023 and beyond."